Altimmune Beats Earnings, Yet Stock Slides 5%

Financial Performance and Liquidity Position

Altimmune Inc (ALT) reported a net loss of $22.6 million for the first quarter of 2026, an increase from the $19.6 million loss recorded in the same period the previous year. The widening of the net loss was primarily driven by increased spending on research and development. Despite the expansion of losses, earnings per share (EPS) showed improvement, moving from -$0.26 in Q1 2025 to -$0.18 in Q1 2026. This performance represented a 25% beat against analyst estimates of -$0.24. However, the market reaction was negative, with the stock declining 4.87% to $3.02 in pre-market trading following the report.

The company’s balance sheet remains robust, bolstered by a $225 million capital raise completed in April 2026. This infusion brought the total cash position to $535 million, resulting in an exceptional current ratio of 18.55 and a low debt-to-equity ratio of 0.16. This strong liquidity position contrasts with the company's operational challenges, as indicated by InvestingPro analysis, which suggests shares are currently overvalued relative to fair value.

Analyst Forecasts and Future Guidance

Management has projected that the second quarter of 2026 will see an EPS of -$0.15, with expectations of gradual loss increases through 2027. Over the past 60 days, estimates for Altimmune’s 2026 loss per share have narrowed from 69 cents to 64 cents. Similarly, loss estimates for 2027 have improved from 73 cents to 64 cents during the same period.

Clinical developments remain a focal point for future valuation. Management plans to initiate Phase III trials for pemvidutide in the treatment of MASH (Metabolic Dysfunction-Associated Steatohepatitis) during the second half of 2026.

Market Sentiment and Valuation Discrepancies

Despite the improved liquidity and narrowing loss estimates, investor sentiment has been bearish. ALT shares have declined 16.7% year-to-date and have dropped 46.53% over the past year, trading near a 52-week low of $2.56. Technical indicators present a mixed picture; while moving averages from the 5-day to the 200-day level suggest a "Buy" outlook with 8 buy signals against 4 sell signals, the 14-day Relative Strength Index (RSI) stands at 53.25, indicating a neutral stance. The MACD indicator is at 0.010, suggesting a buy signal.

Wall Street analysts maintain generally bullish price targets despite the recent price decline. H.C. Wainwright maintains a Buy rating with a price target of $20, representing significant upside potential. Leerink initiated coverage with a Buy rating and a $10 target, while Citizens maintains a Buy rating with an $11 target. Other firms including Evercore ISI, Jefferies, and Barclays have also issued Buy ratings with targets ranging from $18 to $28. Conversely, Goldman Sachs holds a Hold rating with a lower target of $2.50.

Operational Metrics and Industry Comparison

Altimmune’s financial ratios highlight significant deviations from industry norms. The company’s current ratio of 18.55 far exceeds the industry average of 4.97, underscoring its strong short-term liquidity. However, profitability metrics are severely depressed compared to peers. The gross margin for the trailing twelve months is reported at -183,477%, and the net profit margin is -253,002%, both significantly worse than industry averages of -255% and -6,452% respectively.

Sales performance has shown growth, with sales increasing 420% in the most recent quarter and 80% over the trailing twelve months compared to the prior year. This contrasts sharply with the industry, which saw a 48.66% increase in quarterly sales and a 33.48% increase in trailing twelve-month sales. Despite this revenue growth, the company’s price-to-sales ratio is extremely high at 15,774, compared to the industry average of 42.54, indicating that the market is pricing in substantial future growth that has yet to materialize in profitable earnings.